Form 4: Vor Biopharma Director Acquires 30,000 Stock Options

Matthew R. Patterson, a director of Vor Biopharma Inc., acquired 30,000 stock options on May 23, 2024, as part of the company's non-employee director compensation policy.

Summary

• On May 23, 2024, Matthew R. Patterson, a director of Vor Biopharma Inc., was granted 30,000 stock options.
• The options were granted as part of the Issuer's non-employee director compensation policy.
• The exercise price of each option is $1.61.
• The options vest and become exercisable on the earlier of May 23, 2025, or the Issuer's next annual meeting of stockholders following the grant date, subject to continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard compensation practice, indicating confidence in the company's future by incentivizing the director with equity.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard practice for compensating non-employee directors in publicly traded companies, aligning their interests with shareholders through equity ownership.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice among publicly traded companies, particularly in the biotech industry.
• The vesting schedule of one year is fairly standard, aligning with typical annual performance review cycles.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates